Related references
Note: Only part of the references are listed.Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?
Guillaume Robert et al.
AUTOPHAGY (2019)
The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine
Steffan T. Nawrocki et al.
LEUKEMIA (2019)
Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization
Marta Perez-Hernandez et al.
CANCERS (2019)
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Naomi B. Haas et al.
CLINICAL CANCER RESEARCH (2019)
Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo
Xinran Qiao et al.
CANCER COMMUNICATIONS (2018)
Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Jennifer S. Carew et al.
CLINICAL CANCER RESEARCH (2017)
Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
Alessandra Romano et al.
FRONTIERS IN PHARMACOLOGY (2017)
Combined autophagy and HDAC inhibition A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors
Devalingam Mahalingam et al.
AUTOPHAGY (2014)
Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis
Jennifer S. Carew et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Share Paper
